Navigation Links
U.S. FDA Grants Priority Review to Bedaquiline (TMC207) for Multi-Drug Resistant Tuberculosis Treatment
Date:9/5/2012

RARITAN, N.J., Sept. 5, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for bedaquiline (TMC207) to treat pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults as part of combination therapy.

The FDA grants priority review to medicines that may offer major advances in care or provide a treatment option where no adequate therapy exists. Under the Prescription Drug User Fee Act (PDUFA), the FDA will aim to complete its review within six months of the NDA submission. The NDA was submitted June 29.

"There is a growing public health need for new treatment options for multi-drug resistant tuberculosis. If approved, bedaquiline would offer the first in a new class of anti-tuberculosis drugs for patients suffering from this serious and deadly disease," said Wim Parys, M.D., Head of the Infectious Diseases therapeutic area at Janssen. "We are working closely with the FDA and other regulatory agencies in high-burden countries to quickly bring bedaquiline to the patients who need it."  

The regulatory submission was supported by 24-week data from the Phase II clinical development program, which includes an open-label study and a controlled, randomized trial that evaluated the safety and efficacy of bedaquiline versus placebo in the treatment of patients with pulmonary MDR-TB in combination with a background regimen.

Bedaquiline is a diarylquinoline discovered by scientists at Janssen.

About Janssen Research & Development, LLC
At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
2. Community Foundation Announces $2.6 Million In Grants From Centinela Medical Funds
3. U.S. FDA Grants Priority Review to the New Drug Application for Bayers Regorafenib to Treat Patients with Metastatic Colorectal Cancer
4. European Commission Grants Orphan Medicinal Product Designation for Emmaus Medicals Sickle Cell Treatment
5. FDA Grants Orphan Drug Designation To GeNO LLC For Use Of Inhaled Nitric Oxide In Treatment Of Persistant Pulmonary Hypertension Of The Newborn (PPHN)
6. Rep. Fattah Announces More Than $10.7 Million in Grants for Neuroscience, Scientific and Medical Research in Philadelphia
7. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Frost & Sullivan Research Preview: Top 20 Telehealth Markets
10. Webcast Alert: Isis Pharmaceuticals Hosts Dr. Sotirios Tsimikas to Review KYNAMRO™ data Presented at the European Atherosclerosis Society 2012 Meeting
11. HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... 15, 2014 Shire plc (LSE: SHP, NASDAQ: ... Fair Trading (OFT) approval condition to the announced tender offer for ... As a result of the waiver, the transaction is ... the tender offer on January 24, 2014 following the currently scheduled ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2
... 26, 2011 Masimo (NASDAQ: MASI ) today ... Goldman Sachs 32nd Annual Global Healthcare Conference at Terranea in ... 8:40 a.m. Pacific Time.  A live audiocast of the presentation ... .  A replay of the audiocast will be available following ...
... OTC Markets Group Inc. (OTCQX: OTCM), ... the world,s largest electronic marketplace for broker-dealers to trade ... (TSX.V: VRS; OTCQX: VRSEF), a medical device company ... of cancer, is now trading on the OTC market,s ...
Cached Medicine Technology:Masimo to Present at Goldman Sachs 32nd Annual Global Healthcare Conference 2Verisante Technology Inc. Joins OTCQX 2
(Date:4/24/2014)... thought to be boring and irrelevant, could offer an ... , Researcher Dr Milena Furtado, and her team from ... found the heart cell fibroblast is a close relative ... beating heart. , In research published today in ... fibroblasts are unique cells due to their genetic program, ...
(Date:4/24/2014)... of researchers was the first in the world to ... tumour of the jaw. , Ameloblastoma is an odontogenic ... Ameloblastoma is most often found in the posterior of ... resulting in tissue deficiencies in the jaws as well ... could reduce the need for surgery and the recurrence ...
(Date:4/24/2014)... scientist at the University of York reveals that a ... of the nervous system may also play a pivotal ... research team, led by Dr Will Brackenbury, a Medical ... York, has studied how voltage-gated sodium channels assist in ... in the membranes of excitable cells, such as neurons, ...
(Date:4/23/2014)... State University Spokane have developed a new way ... off behind the wheel. , Their recently patented ... more variable in drowsy driversand offers an affordable ... driver drowsiness detection systems. , Van Dongen"Video-based systems ... is drifting out of its lane are cumbersome ...
(Date:4/23/2014)... - Purdue University researchers have developed a way to ... by using tiny gold particles with tails of synthetic ... agricultural and biological engineering, used gold nanoparticles to target ... BRCA1 messenger RNA splice variants, which can indicate the ... these mRNA splice variants in a cell can be ...
Breaking Medicine News(10 mins):Health News:Boring cells could hold the key to heart disease 2Health News:Breast cancer replicates brain development process 2Health News:WSU innovation improves drowsy driver detection 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2
... which comes from the foxglove plant, is normally used to ... the heart and treat heart diseases. The chemical nature of ... University of Wisconsin-Madison to make the drug fight against cancer//., ... works by changing the sugars attached to the drug. By ...
... According to a latest study researchers say health professionals ... manage the risks associated with over the counter drugs. ... one of the most common condition that people choose ... of the other commonly treated ailments include heartburn, migraine, ...
... stutent multi-kinase inhibitors against cancer is undergoing phase 3 ... this years ASCO (American Society of Clinical Oncology) conference. ... mechanism of action – known as Multi-kinase inhibitors. These ... and are found to be very effective. This two ...
... two different types of low fat, low cholesterol diets researchers ... diet consisting of lean meats and other low fat foods ... percent. However, those who consumed a diet rich in plant-based ... as well, lowering their LDL levels by about 9.4 percent. ...
... Researchers say Kelp seaweed may be the next food ... findings from an animal study conducted at the University ... the seaweed effectively reduced levels of estradiol, // a ... rats. The rats also experienced a lengthening of their ...
... say an indirect CT venography ( CTV ) could identify ... break free, travel to the lung, and block an artery ... arteries are not visible in a commonly used lung scan, ... presence of these blood clots in the lung. ...
Cached Medicine News:
... for use with GIA DST ... with Titanium Staples)., ,The ... and the SGIA™ Knifeless Stapler ... pediatric and thoracic surgical procedures ...
The Reusable Purse String Clamp is intended for use in the mechanical construction of a purse string suture. The clamp can be used on any part of the gastrointestinal tract except the esophagus....
... Device for use with VALTRAC™ ... Ring)., ,The Purstring™ Device ... and esophageal surgery for the ... and is intended for use ...
... to create an automatic purse-string with ... 45 disposable instrument has application in ... surgery for temporary and permanent purse-string ... disposable instrument has application in intestinal, ...
Medicine Products: